$TSHA News
Last published 5d ago
- 5d agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 5d agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company...
- 6d agoTSHATaysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12GlobeNewswireDALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 2mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 3mo agoTSHATaysha Gene Therapies Second Quarter 2026 Financial Results Conference Call - TAYSHA GENE THERAPIES INCEarnings Call TranscriptsHello, and welcome to the Tayshia Gene Therapy's second quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-a
- 3mo agoTSHATaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in
- 3mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 3mo agoTSHATaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11GlobeNewswireDALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 3mo agoTSHATaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett SyndromeGlobeNewswireCAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (NASDAQ:TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus
- 4mo agoTSHATaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireDALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 4mo agoTSHATaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireDALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 4mo agoTSHATaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett SyndromeGlobeNewswireCompleted dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated
- 5mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 6mo agoTSHATaysha Gene Therapies First Quarter 2026 Financial Results Conference CallTAYSHA GENE THERAPIES INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the Tayshia Gene Therapy's first quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentati
- 6mo agoTSHATaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireReaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following recent breakthrough
- 6mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, May 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 6mo agoTSHATaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6GlobeNewswireDALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 6mo agoTSHATaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual MeetingGlobeNewswireIn vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by
- 7mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 7mo agoTSHATaysha Gene Therapies Full-Year 2025 Financial Results Conference CallTAYSHA GENE THERAPIES INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the Taysha Jean Therapy's full year 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation,
- 8mo agoWVEDNLIMRNAGMTX+6FDA reversals leave investors worrying about the fates of other experimental drugsCNBCInvestors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
- 8mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 9mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 11mo agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireTSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the
- 1y agoTSHATaysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4GlobeNewswireDALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeGlobeNewswireThe 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and
- 1y agoTSHATaysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual MeetingGlobeNewswirePreviously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett SyndromeGlobeNewswireBreakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA alignment on
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 1y agoTSHATaysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTSHATaysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireCommenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient
- 1y agoTSHATaysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12GlobeNewswireDALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical ProgramGlobeNewswireRecently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of
- 1y agoTSHATaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireDALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireDALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102GlobeNewswireNatural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome
- 1y agoTSHATaysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireObtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and
- 1y agoTSHATaysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15GlobeNewswireDALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus
- 1y agoTSHATaysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireHigh dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4) across both REVEAL
- 1y agoTSHATaysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26GlobeNewswireDALLAS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
- 1y agoTSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies